Please login to the form below
tenofovir disoproxil
This page shows the latest tenofovir disoproxil news and features for those working in and with pharma, biotech and healthcare.
ViiV takes on Gilead’s PReP dominance with HIV injectable data
emtricitabine/tenofovir disoproxil fumarate). ... Gilead is trying to position its recently-approved two-drug combination Descovy (emtricitabine/tenofovir alafenamide) as a successor to Truvada that is safer, with significant improvements on measures of
Latest news
-
NHS England will make PrEP for HIV available in April
The PrEP Impact Trial is using Mylan's generic version of Gilead Sciences’ antiretroviral therapy Truvada (emtricitabine/tenofovir disoproxil) but is due to come to an end in October.
-
Gilead builds case for Descovy PrEP after FDA approval
Descovy (emtricitabine/tenofovir alafenamide) claimed its FDA approval for PrEP last week – becoming only the second drug for this use since Gilead’s Truvada (emtricitabine/tenofovir disoproxil fumarate) got a green
-
Gilead claims FDA okay for Descovy as second PrEP option
Descovy (emtricitabine and tenofovir alafenamide) has been cleared for adolescents and adults who are at risk of HIV infection because they have sex with an HIV-positive partner. ... In a statement, the FDA said that Descovy’s efficacy in preventing
-
MSD claims EU approval for two HIV products
The pair – non-nucleoside reverse transcriptase inhibitor (NNRTI) Pifeltro (doravirine) and single-tablet combination Delstrigo (doravirine, lamivudine and tenofovir disoproxil fumarate) – are a much-needed bolster for Merck’s HIV portfolio,
-
ViiV chalks up another win for two-drug HIV regimen
effects. Last month for example, ViiV showed that an oral formulation of Tivicay with nucleoside RTI Epivir (lamivudine) was as effective as a three-drug cocktail of dolutegravir plus tenofovir disoproxil ... Gilead’s new fixed-dose Biktarvy
More from news
Approximately 5 fully matching, plus 39 partially matching documents found.
Latest Intelligence
-
Choices, choices: the rapidly evolving HIV treatment landscape
With Triumeq signalling the approval of the first STR without tenofovir disoproxil fumarate (TDF) it can, uniquely, be used in those patients with impaired kidney function. ... Gilead, in hot pursuit, is in phase III of development of a new regimen where
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Regeneron says antibody for COVID-19 could be ready this year
- Amgen adds Otezla to the COVID-19 candidate list
- UK clears NHS use of Gilead’s remdesivir for COVID-19 patients
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- NICE approves Roche’s Tecentriq in TNBC after revising deal
- CEPI-backed coronavirus vaccine from Novavax starts trials
- IFPMA industry association conference: ‘no-one left behind’ on coronavirus vaccine
- Roche/Gilead tag team fights COVID-19 with Actemra/remdesivir
- GSK plans to produces one billion doses of vaccine adjuvant for COVID-19
- The big issue
- The field team are off the road! What should they do next?
- INFOGRAPHIC 02: The Importance of clinical study websites
PMHub
Valid Insight
Valid Insight is an award-winning pharmaceutical global market access consultancy....
Latest intelligence
- The big issue
- Whether you want to lead or follow, you need to understand the elephant in the C-suite...
- INFOGRAPHIC 02: The Importance of clinical study websites
- Here’s a infographic of why clinical study websites are important to patient recruitment and retention strategies…...
- Working with, Advocating for, and Empowering Patients
- A holistic view of how to work with patients virtually...
Quick links
Infographics
